Expertise in
6
conditions

Dr. Barry J. Byrne

Pediatrics
UF Health Pediatric Infusion Center & Specialties Clinic
1600 SW Archer Rd Fl Fourth, 
Gainesville, FL 
Accepting New Patients
Expertise in
6
conditions
UF Health Pediatric Infusion Center & Specialties Clinic
1600 SW Archer Rd Fl Fourth, 
Gainesville, FL 

Overview

Barry Byrne is a Pediatrics provider practicing medicine in Gainesville, Florida.

Dr. Byrne is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Pompe Disease, Hereditary Ataxia, Hypotonia, Infantile Neutropenia, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 201 peer reviewed articles and participating in 20 clinical trials. Dr. Byrne is currently accepting new patients in some locations.

Specialties

Pediatrics

Licenses

Pediatric Cardiology in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

UF Health Pediatric Infusion Center & Specialties Clinic
1600 SW Archer Rd Fl Fourth, Gainesville, FL 32610

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Randomized, Controlled, Open-label, Single-ascending Dose, Phase I/II Study to Investigate the Safety and Tolerability, and Efficacy of Intravenous SGT-001 in Male Adolescents and Children With Duchenne Muscular Dystrophy
A Randomized, Controlled, Open-label, Single-ascending Dose, Phase I/II Study to Investigate the Safety and Tolerability, and Efficacy of Intravenous SGT-001 in Male Adolescents and Children With Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: August 10, 2026
Intervention Type: Genetic
Study Drug: SGT-001 Adeno-Associated Virus Microdystrophin Construct
Study Phase: Phase 1/Phase 2
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
Enrollment Status: Completed
Publish Date: October 23, 2025
Intervention Type: Drug
Study Drugs: ATB200, AT2221
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Natural History Study in Children With a TECPR2 Mutation
A Natural History Study in Children With a TECPR2 Mutation
Enrollment Status: Completed
Publish Date: September 11, 2023
Expanded Access Trial of Systemic Delivery of Aspartoacylase ASPA (rAAV9-CB6-AspA) Gene Vector in a Single Patient With Canavan Disease
Expanded Access Trial of Systemic Delivery of Aspartoacylase ASPA (rAAV9-CB6-AspA) Gene Vector in a Single Patient With Canavan Disease
Enrollment Status: No_longer_available
Publish Date: August 23, 2023
Intervention Type: Drug
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: February 02, 2023
Intervention Type: Drug
Study Drug: Givinostat
Study Phase: Phase 3
A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment
A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment
Enrollment Status: Completed
Publish Date: July 06, 2022
Intervention Type: Drug
Study Phase: Phase 1
Evaluation of Re-administration of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV9-DES-hGAA) in Patients With Late-Onset Pompe Disease (LOPD)
Evaluation of Re-administration of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV9-DES-hGAA) in Patients With Late-Onset Pompe Disease (LOPD)
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Drug, Other, Genetic
Study Drugs: Rapamycin, Rituxan, Diphenhydramine, Acetaminophen, Lidocaine, LMX 4 Topical Cream, Adeno-Associated Virus Acid Alpha Glucosidase
Study Phase: Phase 1
A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: December 07, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

201 Total Publications

Neonatal systemic gene therapy restores cardiorespiratory function in a rat model of Pompe disease.
Neonatal systemic gene therapy restores cardiorespiratory function in a rat model of Pompe disease.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 01, 2026
Similar Doctors
Expertise in
2
conditions
Expertise in
2
conditions
Referral may be required

Uf Health Medical Lab-Shands Hospital

1600 SW Archer Rd, 
Gainesville, FL 
 (1.3 miles away)
352-273-5400
Languages Spoken:
English
See accepted insurances

Eric Nelson is a Pediatrics provider practicing medicine in Gainesville, Florida. Dr. Nelson is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Diarrhea and Undescended Testicle.

Expertise in
1
conditions
Expertise in
1
conditions
Referral may be required

UF Health Comprehensive Skull Base Surgery Center

1505 SW Archer Rd, 
Gainesville, FL 
 (1.3 miles away)
352-273-6990
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Haller is a Pediatrics provider practicing medicine in Gainesville, Florida. Dr. Haller is highly rated in 1 condition, according to our data. His clinical expertise encompasses Type 1 Diabetes (T1D), Celiac Disease, Malabsorption, and Exocrine Pancreatic Insufficiency. Dr. Haller is currently accepting new patients.

Expertise in
1
conditions
Expertise in
1
conditions
Referral may be required

Uf Health Pediatric Specialties-Medical Plaza

1549 Gale Lemerand Dr Fl Second, 
Gainesville, FL 
 (0.1 miles away)
352-265-8250
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Desmond Schatz is a Pediatrics provider practicing medicine in Gainesville, Florida. Dr. Schatz is highly rated in 1 condition, according to our data. His clinical expertise encompasses Type 1 Diabetes (T1D), Exocrine Pancreatic Insufficiency, Chronic Pancreatitis, and Childhood Pancreatitis. Dr. Schatz is currently accepting new patients.

Frequently Asked Questions about Dr. Barry J. Byrne

How do I make an appointment with Dr. Barry J. Byrne?

You can book an appointment with Dr. Barry J. Byrne by calling their office at 352-265-8250. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Barry J. Byrne a top-rated expert for Pompe Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Barry J. Byrne is classified as an Elite expert for Pompe Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Barry J. Byrne specialize in?

While Dr. Barry J. Byrne is a Pediatrics, they have specific expertise in Pompe Disease, Hereditary Ataxia, and Hypotonia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. Barry J. Byrne participate in research or clinical trials?

Yes. Dr. Barry J. Byrne has published 201 articles and abstracts on conditions like Pompe Disease. You can view a list of Dr. Barry J. Byrne's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Barry J. Byrne accept my insurance?

Dr. Barry J. Byrne accepts most major insurance plans, including Blue Shield of California and Florida Blue. We recommend calling the office directly at 352-265-8250 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Byrne's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile